• Overview
  • Eligibility
  • More info
  • Locations

Nucala® Subcutaneous Injection Special Drug Use Investigation (Long-Term) (NCT03028480)

This study is a special drug use investigation program of NUCALA (a brand name for Mepolizumab) administered subcutaneously (SC). In this study the information regarding the safety and effectiveness of long term use of NUCALA after subcutaneous injection will be collected from Asthma subjects in daily clinical practice. The observation period per subject will be 52 weeks from the initiation of NUCALA treatment with follow-up investigation for 2 years after the observation period. NUCALA is a registered trademark of the GlaxoSmithKline [GSK] group of companies
  • Drug: NUCALA Injection
    Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
    Ages eligible for Study
    all
    Genders eligible for Study
    All
    Accepts Healthy Volunteers
    No
    Inclusion Criteria:
    • Subjects receiving NUCALA for the first time for treatment of bronchial asthma (a refractory asthma whose symptoms are inadequately controlled despite receiving standard asthma medications)
    Exclusion Criteria:
    • No exclusion criteria
    Status:
    active not recruiting
    Type:
    Observational
    Phase:
    -
    Start:
    31 December, 2016
    Updated:
    25 January, 2017
    Participants:
    1
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!